ExpreS2ion Biotech Holding AB (publ) (EXPRS2.ST)
SEK 19.08
(-1.45%)
SEK 19.08
(-1.45%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -55.88 Million SEK | 48.79% |
| 2022 | -109.12 Million SEK | -210.07% |
| 2021 | -35.19 Million SEK | 66.31% |
| 2020 | -104.45 Million SEK | -2561.2% |
| 2019 | -3.92 Million SEK | 26.37% |
| 2018 | -5.33 Million SEK | -272.02% |
| 2017 | -1.43 Million SEK | -271.24% |
| 2016 | -386 Thousand SEK | -137.97% |
| 2015 | 1.01 Million SEK | 164.37% |
| 2014 | 384.55 Thousand SEK | 666.33% |
| 2013 | -67.9 Thousand SEK | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -66.5 Million SEK | -13.82% |
| 2024 Q1 | -59.91 Million SEK | -7.2% |
| 2023 Q3 | -75.09 Million SEK | 12.87% |
| 2023 Q4 | -55.88 Million SEK | 25.58% |
| 2023 Q1 | -69.96 Million SEK | 35.88% |
| 2023 Q2 | -86.18 Million SEK | -23.18% |
| 2023 FY | -55.88 Million SEK | 48.79% |
| 2022 Q1 | -37.7 Million SEK | -7.12% |
| 2022 FY | -109.12 Million SEK | -210.07% |
| 2022 Q4 | -109.12 Million SEK | 26.14% |
| 2022 Q3 | -147.75 Million SEK | 10.93% |
| 2022 Q2 | -165.89 Million SEK | -340.03% |
| 2021 Q1 | -80.88 Million SEK | 22.57% |
| 2021 Q3 | -140.03 Million SEK | -31.71% |
| 2021 Q2 | -106.32 Million SEK | -31.46% |
| 2021 FY | -35.19 Million SEK | 66.31% |
| 2021 Q4 | -35.19 Million SEK | 74.87% |
| 2020 FY | -104.45 Million SEK | -2561.2% |
| 2020 Q1 | -4.24 Million SEK | -8.1% |
| 2020 Q2 | -5.18 Million SEK | -22.2% |
| 2020 Q3 | -19.31 Million SEK | -272.52% |
| 2020 Q4 | -104.45 Million SEK | -440.78% |
| 2019 Q3 | -1.73 Million SEK | 60.42% |
| 2019 FY | -3.92 Million SEK | 26.37% |
| 2019 Q4 | -3.92 Million SEK | -126.49% |
| 2019 Q2 | -4.37 Million SEK | 51.09% |
| 2019 Q1 | -8.95 Million SEK | -67.92% |
| 2018 FY | -5.33 Million SEK | -272.02% |
| 2018 Q2 | -11.8 Million SEK | 33.31% |
| 2018 Q4 | -5.33 Million SEK | 41.36% |
| 2018 Q1 | -17.7 Million SEK | -1135.66% |
| 2018 Q3 | -9.09 Million SEK | 23.01% |
| 2017 Q2 | -413 Thousand SEK | 76.6% |
| 2017 Q1 | -1.76 Million SEK | 71.8% |
| 2017 Q4 | -1.43 Million SEK | 63.52% |
| 2017 FY | -1.43 Million SEK | -271.24% |
| 2017 Q3 | -3.92 Million SEK | -851.09% |
| 2016 Q1 | 683.27 Thousand SEK | 0.0% |
| 2016 Q4 | -6.25 Million SEK | 29.46% |
| 2016 Q3 | -8.87 Million SEK | -1446.13% |
| 2016 Q2 | 659 Thousand SEK | -3.55% |
| 2016 FY | -386 Thousand SEK | -137.97% |
| 2015 FY | 1.01 Million SEK | 164.37% |
| 2014 FY | 384.55 Thousand SEK | 666.33% |
| 2013 FY | -67.9 Thousand SEK | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Active Biotech AB (publ) | -33.2 Million SEK | -68.331% |
| Biovica International AB (publ) | -58.73 Million SEK | 4.854% |
| Cantargia AB (publ) | -139.74 Million SEK | 60.009% |
| CombiGene AB (publ) | -101.44 Million SEK | 44.907% |
| Cyxone AB (publ) | -16.67 Million SEK | -235.249% |
| Diagonal Bio AB (publ) | -2.97 Million SEK | -1780.417% |
| Elicera Therapeutics AB (publ) | -29.38 Million SEK | -90.199% |
| Fluicell AB (publ) | -2.76 Million SEK | -1922.657% |
| Infant Bacterial Therapeutics AB (publ) | -329.06 Million SEK | 83.017% |
| Mendus AB (publ) | -96.29 Million SEK | 41.963% |
| Isofol Medical AB (publ) | -138.14 Million SEK | 59.546% |
| I-Tech AB | -83.26 Million SEK | 32.879% |
| Intervacc AB (publ) | -88.16 Million SEK | 36.608% |
| Lipigon Pharmaceuticals AB (publ) | -31.92 Million SEK | -75.043% |
| Magle Chemoswed Holding AB (publ) | 53.22 Million SEK | 205.003% |
| Modus Therapeutics Holding AB (publ) | -19.06 Million SEK | -193.211% |
| OncoZenge AB (publ) | -12.62 Million SEK | -342.591% |
| Sprint Bioscience AB (publ) | -49.93 Million SEK | -11.92% |
| Xbrane Biopharma AB (publ) | 166.07 Million SEK | 133.651% |
| Lipum AB (publ) | -8.46 Million SEK | -560.201% |
| Alligator Bioscience AB (publ) | -50.02 Million SEK | -11.725% |
| Ziccum AB (publ) | -2.13 Million SEK | -2515.161% |
| BioArctic AB (publ) | -606.58 Million SEK | 90.787% |
| Genovis AB (publ.) | -43.94 Million SEK | -27.184% |
| Camurus AB (publ) | -1.16 Billion SEK | 95.204% |
| IRLAB Therapeutics AB (publ) | -83.74 Million SEK | 33.265% |
| Bio-Works Technologies AB (publ) | -39.38 Million SEK | -41.907% |
| Aptahem AB (publ) | 2.9 Million SEK | 2021.378% |
| Vicore Pharma Holding AB (publ) | -333.62 Million SEK | 83.249% |
| Xspray Pharma AB (publ) | -129.49 Million SEK | 56.843% |
| Kancera AB (publ) | -45.69 Million SEK | -22.31% |
| Saniona AB (publ) | 40.44 Million SEK | 238.171% |
| Spago Nanomedical AB (publ) | -45.21 Million SEK | -23.595% |
| AcouSort AB (publ) | -23.98 Million SEK | -132.994% |
| Xintela AB (publ) | -7.8 Million SEK | -615.661% |
| Abliva AB (publ) | -57.24 Million SEK | 2.365% |
| Karolinska Development AB (publ) | -82.2 Million SEK | 32.014% |
| Amniotics AB (publ) | -5.63 Million SEK | -892.294% |
| 2cureX AB (publ) | -13.4 Million SEK | -316.966% |
| Asarina Pharma AB (publ) | -2.16 Million SEK | -2486.118% |
| Calliditas Therapeutics AB (publ) | 5.4 Million SEK | 1134.926% |
| Hansa Biopharma AB (publ) | 134.7 Million SEK | 141.487% |
| Biosergen AB | -1.88 Million SEK | -2867.924% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 20.51 Million SEK | 372.482% |
| Corline Biomedical AB | -17.01 Million SEK | -228.509% |
| NextCell Pharma AB | -46.79 Million SEK | -19.438% |
| Nanologica AB (publ) | -9.38 Million SEK | -495.292% |
| LIDDS AB (publ) | -13.51 Million SEK | -313.603% |
| Egetis Therapeutics AB (publ) | -194.7 Million SEK | 71.296% |
| BioInvent International AB (publ) | -236.3 Million SEK | 76.35% |
| SynAct Pharma AB | -61.75 Million SEK | 9.508% |
| Annexin Pharmaceuticals AB (publ) | -21.41 Million SEK | -160.967% |
| Stayble Therapeutics AB (publ) | -13.22 Million SEK | -322.445% |
| Alzinova AB (publ) | -21.22 Million SEK | -163.29% |
| Ascelia Pharma AB (publ) | -20.79 Million SEK | -168.773% |
| Oncopeptides AB (publ) | -66.92 Million SEK | 16.488% |
| Pila Pharma AB (publ) | -5.18 Million SEK | -978.689% |
| Guard Therapeutics International AB (publ) | -83.74 Million SEK | 33.263% |
| Scandinavian ChemoTech AB (publ) | -923 Thousand SEK | -5954.821% |
| Simris Alg AB (publ) | 85.07 Million SEK | 165.69% |
| Diamyd Medical AB (publ) | -82.08 Million SEK | 31.918% |